日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

一项恩扎卢胺联合AKT抑制剂AZD5363（capivasertib）治疗转移性去势抵抗性前列腺癌患者的I期剂量递增研究

期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2020.01.074
Kolinsky, M P; Rescigno, P; Bianchini, D; Zafeiriou, Z; Mehra, N; Mateo, J; Michalarea, V; Riisnaes, R; Crespo, M; Figueiredo, I; Miranda, S; Nava Rodrigues, D; Flohr, P; Tunariu, N; Banerji, U; Ruddle, R; Sharp, A; Welti, J; Lambros, M; Carreira, S; Raynaud, F I; Swales, K E; Plymate, S; Luo, J; Tovey, H; Porta, N; Slade, R; Leonard, L; Hall, E; de Bono, J S
AKT
肿瘤
前列腺癌
肿瘤免疫
发表日期：2020
文献求助 收藏

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

Vistusertib（双重m-TORC1/2抑制剂）联合紫杉醇治疗高级别浆液性卵巢癌和鳞状非小细胞肺癌患者

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdy245
Basu, B; Krebs, M G; Sundar, R; Wilson, R H; Spicer, J; Jones, R; Brada, M; Talbot, D C; Steele, N; Ingles Garces, A H; Brugger, W; Harrington, E A; Evans, J; Hall, E; Tovey, H; de Oliveira, F M; Carreira, S; Swales, K; Ruddle, R; Raynaud, F I; Purchase, B; Dawes, J C; Parmar, M; Turner, A J; Tunariu, N; Banerjee, S; de Bono, J S; Banerji, U
肺癌
肿瘤
肿瘤免疫
卵巢癌
ORC1
细胞生物学
发表日期：2018
文献求助 收藏

Intercellular ultrafast Ca(2+) wave in vascular smooth muscle cells: numerical and experimental study

血管平滑肌细胞内细胞间超快Ca(2+)波：数值和实验研究

期刊:Scientific Reports
影响因子:3.9
doi:10.1038/srep31271
Quijano, J C; Raynaud, F; Nguyen, D; Piacentini, N; Meister, J J
细胞生物学
发表日期：2016
文献求助 收藏

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors

I类和I/IV类双重磷脂酰肌醇3-激酶（PI3K）抑制剂的临床前发现和临床开发进展

期刊:Current Medicinal Chemistry
影响因子:3.5
doi:10.2174/092986711796011229
Shuttleworth, S J; Silva, F A; Cecil, A R L; Tomassi, C D; Hill, T J; Raynaud, F I; Clarke, P A; Workman, P
信号转导
发表日期：2011
文献求助 收藏

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

适用于抗癌药物临床试验的生物标志物方法验证

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6605910
Cummings, J; Raynaud, F; Jones, L; Sugar, R; Dive, C
肿瘤
肿瘤免疫
发表日期：2010
文献求助 收藏

A Phase I study of the angiogenesis inhibitor SU5416 (semaxanib) in solid tumours, incorporating dynamic contrast MR pharmacodynamic end points.

一项针对实体瘤的血管生成抑制剂 SU5416（semaxanib）的 I 期研究，纳入了动态对比 MR 药效学终点

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6602797
O'Donnell A, Padhani A, Hayes C, Kakkar A J, Leach M, Trigo J M, Scurr M, Raynaud F, Phillips S, Aherne W, Hardcastle A, Workman P, Hannah A, Judson I
肿瘤
Angiogenesis
血管生成
发表日期：2005
文献求助 收藏

A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

顺式二氨二氯(2-甲基吡啶)铂II (AMD473) 的 I 期临床和药理学研究

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/sj.bjc.6600854
Beale, P; Judson, I; O'Donnell, A; Trigo, J; Rees, C; Raynaud, F; Turner, A; Simmons, L; Etterley, L
AMD
发表日期：2003
文献求助 收藏